Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $576.73M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.98M
Average 2.56M
ANNX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Annexon, Inc.NASDAQ: ANNX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $1.91M fell 37.3% year over year, ahead of the -44.7% change in trailing-twelve-month other income / expenses. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at +38.6% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -37.3% holds above the trailing-twelve-month pace of -44.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 9.72M USD
- Year-over-year change
- -38.8%
- 4-year CAGR
- +123.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.72M | -38.8% |
| FY2024 | 2024-12-31 | 15.87M | +67.3% |
| FY2023 | 2023-12-31 | 9.49M | +159.7% |
| FY2022 | 2022-12-31 | 3.65M | +836.4% |
| FY2021 | 2021-12-31 | 390K | — |
Other Income / Expenses vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -44.7% is the 6th highest of 11, against a peer median of -41.0%.
- Over three fiscal years its annual growth of +38.6% compares with a peer median of +51.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.23M USD | +206.4% | +46.5% | 52.6% | |
| LTM Sep 2026 | $21.05M USD | -14.7% | — | 296.6% | |
| LTM Mar 2026 | $20.28M USD | -10.8% | — | 35.0% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $18.29M USD | -91.0% | +350.3% | 247.2% |
| LTM Mar 2026 | $11.83M USD | +129.2% | — | 22.0% | |
| LTM Mar 2026 | $10.82M USD | -0.5% | +57.2% | 129.3% | |
| LTM Mar 2026 | $8.58M USD | -44.7% | +38.6% | — | |
| LTM Mar 2026 | -€440.14K EUR | -104.4% | -1.4% | 1500.6% | |
| LTM Mar 2026 | -CHF 1.47M CHF | -268.3% | — | 39.8% | |
| LTM Mar 2026 | -$67.43M USD | -67.3% | — | 29.0% | |
| FY2025 | -€84.2M EUR | -2484.3% | — | — | |
| Peer median (excluding ANNX) | — | -41.0% | +51.9% | 52.6% | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 3.45M | 3.69M |
| Gross Profit | 0 | 0 | 0 | (3.45M) | (3.69M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 100.07M | 112.5M | 113.76M | 119.45M | 184.7M |
| Selling, General & Admin | 30.65M | 30.95M | 28.02M | 34.63M | 31.71M |
| Operating Expenses | 130.71M | 145.6M | 143.72M | 150.62M | 212.72M |
| Depreciation & Amortization | 2.14M | 2.15M | 2.15M | 3.45M | 2.65M |
| EBITDA | (128.18M) | (139.8M) | (132.09M) | (134.75M) | (204.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (130.71M) | (145.6M) | (143.72M) | (154.07M) | (216.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 390K | 3.65M | 9.49M | 15.87M | 9.72M |
| Income Before Tax | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| EPS (Diluted) | (3.34) | (2.60) | (1.77) | (1.01) | (1.34) |
| Weighted Avg Shares | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
| Weighted Avg Shares (Diluted) | 38.32M | 54.67M | 75.67M | 137.4M | 155.11M |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.